Surgical site infections (SSIs) are frequent complications in neurosurgical patients, often worsened by perioperative hyperglycemia. This randomized, controlled trial will compare intensive glycemic control (continuous insulin infusion, 140-180 mg/dL) with standard care (subcutaneous insulin, 81-180 mg/dL) in 544 patients. The primary outcome is SSI occurrence within 90 days post-surgery. Results aim to guide optimal glycemic management for SSI prevention in neurosurgery.
Adults aged ≥18 years
Patients undergoing elective cranial neurosurgical procedures classified as clean surgeries
Patients who underwent any surgical or neurosurgical procedure within 30 days prior to enrollment
Presence of active infection at any site
Patients undergoing emergency or urgent neurosurgical procedures
Patients with trauma and exposed brain tissue